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disabilities in HIV-1-infected subjects?
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ABSTRACT 
Objective: We evaluated the association between cognitive deficits and leukocyte telomere 
length (LTL) in HIV-1-infected individuals. Design: 73 HIV-1-infected patients undergoing 
neuropsychological evaluation and 91 healthy controls were included in this study. Fifteen 
HIV-1 positive patients did not have cognitive disorders whereas 26 had asymptomatic 
neurocognitive disorder (ANI), 13 presented mild to moderate neurocognitive disorder 
(MND), and 10 had HIV-associated dementia (HAD). Methods: DNA from the peripheral 
blood of HIV-1-infected patients was used for measurement of telomere length by real-time 
PCR. HIV-1 viral load was determined in blood. Results: LTL decreased with age in healthy 
controls (p=0.0001). Regardless of the HIV status, age-matched LTL from HIV patients, 
including those with ANI and MND, were shortened in comparison to the healthy control 
group (p=0.0073); however, no association was found among the HIV-1-infected individuals 
with cognitive deficits (p=0.01). In addition, no gender-related association with LTL was 
observed (p=0.80), smoking, physical exercise, and plasma viral load were not correlated to 
telomere length (p=0.66). Conclusions: We concluded that leukocyte telomere length may 
not be a marker of cellular senescence in individuals with HIV infection and neurocognitive 
disorders.
KEYWORDS: Cell aging. Neurocognitive disorders. Real-time polymerase chain reaction. 
AIDS. Dementia complex.
INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) infection remains a serious 
public health problem1. There are more than 40 million HIV-infected patients 
worldwide, most of them showing some degree of cognitive impairment. The use 
of highly active antiretroviral therapy (HAART) has changed the natural history of 
the infection2, increasing patients’ life expectancy but heightening the chance of 
damage to the central nervous system (CNS).
The mechanism of CNS lesions involves virus entry into the CNS during the early 
course of infection through the disruption of the blood-brain barrier (BBB). This 
event results from the neurotoxic activity of several HIV-1 proteins, including gp120, 
tat, vpr, and others3. In addition, there are alterations both in the CNS homeostasis, 
involving the metabolic integrity of the BBB, and in the metabolism of astrocytes, 
microglia, resident macrophages and perivascular space4.
Due to the processes described above, neurocognitive disorders may ensue. 
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According to the classification revised by the working 
group assembled by Frascatti in 2007, neurocognitive 
disorders associated with HIV (HAND) are classified as 
asymptomatic neurocognitive impairment (ANI), mild 
cognitive disorder (MND), and HIV-associated dementia 
(HAD)5. A significant increase in the incidence of cognitive 
dysfunction in HIV-infected patients has occurred in the 
last years6.
The cognitive decline is associated with age and may be 
accelerated in patients with HIV. This fact may be related 
to telomere shortening7,8. Telomeres are nucleoproteins 
consisting of several thousand DNA repeats of TTAGGG 
in association with a protein complex at the end of linear 
chromosomes9. Telomeres act to protect the chromosome 
ends from recognition as damaged or infectious DNA10,11. 
Telomeric DNA shortens during each cell replication 
and, when critically short, telomere length (TL) can 
trigger the cell to enter replicative senescence or apoptosis 
and, in cells that continue to divide, to chromosomal 
abnormality11-15. The etiology of immunosenescence 
is multifactorial and reflects exposure to external 
pathogens, persistent viral infections, obesity, physical and 
psychological stress, and thymic involution, among other 
events throughout an individual’s life16.
HIV infection can lead to chronic immune activation, 
oxidative stress, and inflammation17 and is also correlated 
with shortened telomeres18 in vivo19,20 and inhibition of 
telomerase in vitro21. Chronic immune activation due to 
persistence of circulating HIV virions may play a key role 
in the senescent pathway. Activated cells undergo clonal 
expansion in response to viral persistence, resulting in 
differentiation and accumulation of nonfunctional senescent 
cells22. 
Comparing TL in HIV-infected and HIV-uninfected 
individuals may be an important step toward understanding 
why HIV-infected individuals have a higher incidence 
of age-related diseases23. Thus, the objective of this 
work was to evaluate the impact of HIV infection in 
the immunosenescence of leukocytes, in patients with 
neurocognitive disturbance, in addition to providing 
possible biomarkers to this pathological code, independent 
of neurocognitive compromise. Some risk factors, such 
as smoking, physical activity and other factors were also 
evaluated.
MATERIAL AND METHODS
Mean TL was measured by qPCR based on a modification 
of the method described by Cawthon in 2002, as previously 
described24-26. To ensure the quality of our data, all samples 
(100 ng) were loaded in agarose gel 1% to check the DNA 
integrity. Samples that were not degraded were submitted 
to qPCR. Basically, qPCR was conducted in triplicate and 
reactions included: genomic DNA (1.6 ng), 2x Rotor-
Gene SYBR Green, PCR Master Mix (Qiagen, Hilden, 
Germany), RNase-free water (Qiagen, Germany), primer 
Tel Forward (300 nM) (CGGTTTGTTTGGGTTTGGG
TTTGGGTTTGGGTTTGGGTT) and Tel Reverse (300 
nM) (GGCTTGCCTTACCCTTACCCTTACCCTTACCC
TTACCCT) or primer single gene forward (36B4 F–300 
nM) (CAGCAAGTGGGAAGGTGTAATCC) and 
s i n g l e  g e n e  r e v e r s e  ( 3 6 B 4  R – 5 0 0  n M ) 
(CCCATTCTATCATCAACGGGTACAA), in a 24 µL 
final reaction. All qPCR reactions were prepared on a 
QIAgility automated pipettor (Qiagen, California, USA) 
and amplification was conducted in the Rotor-Gene Q 
real-time PCR cycler as follow: 5 min at 95 °C, 25 cycles 
(telomere reaction) and 35 cycles (single gene reaction) of 
7 s at 98 °C and 10 s at 60 °C (telomere) or 10 s at 58 °C 
(single gene). The TL for each sample was determined 
using the telomere to single copy gene ratio (T/S ratio) by 
calculating the ΔCt [Ct(telomere)/Ct(single gene)]. The 
T/S ratio for each sample (x) was normalized to the mean 
T/S ratio of reference sample [2–(ΔCtx−ΔCtr)  = 2−ΔΔCt], 
which was also used for the standard curve, both as a 
reference sample and as a validation sample. In every 
run, two reference samples were included to validate 
each reaction. The experiment was considered acceptable 
if control sample T/S ratio ranged within the 95% 
variation interval (0.95–1.05). The correlation between TL 
measurements of an independent cohort (n = 76) by qPCR 
and Southern blot was used to convert T/S ratio values in 
kilobases. The linear regression equation used was: telomere 
length (kb) = 4.330x+5.07 (R2 = 0.55; p<0.0001), where x 
corresponds to the T/S ratio value.
Ethics
The Scientific Committee and the Research Ethics 
Committee, both from the Institute of Infectious Diseases 
Emilio Ribas, São Paulo, Brazil, approved this study 
(034/11). Participant samples and other research data were 
collected within one year from the neuropsychological 
analysis of the participants of this study. Detailed history 
of each individual, including information as an indicator of 
physical activity practice and its relationship with the quality 
of life of young adults (through the IPAQ questionnaire), 
time of HIV infection, whether the participant is a smoker 
or not; Data on CD4 + T-cell lymphocyte counts and nadir 
of CD4+ counts were also obtained. All participants signed 
a written informed consent form.
The application of neuropsychological tests was 
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performed by a team of highly trained neuropsychologists 
at the Institute of Infectious Diseases Emilio Ribas. The data 
collection from patients included in this study comprised 
five sections: 1) socio-demographic survey; 2) medical 
history and survey of functional status; 3) questionnaire 
of subjective neurological symptoms; 4) complete 
neurological evaluation; 5) neuropsychological screening 
test (International HIV Dementia Scale) followed by 
neuropsychological tests.
In addition to establishing the neuropsychological 
profile of patients, we evaluated the indicator of physical 
activity practice and its relationship with the quality of life 
of young adults of physical activity using the International 
Physical Activity Questionnaire (IPAC) (Table 1), developed 
by the World Health Organization (WHO, 1998).
A Neurology American Academy 2007 criterion 
was used to characterize patient groups: asymptomatic 
neurocognitive disorder (ANI), MND and HAD5 
Neuropsychological tests evaluated the following criteria: 
attention/concentration, information processing speed, 
executive function, reasoning, abstraction, memory/
learning, visuospatial capacity and operational motor. 
Exclusion criteria were individuals presenting depression 
during neuropsychological tests, individuals using abusive 
and psychotropic drugs, pregnant women, and individuals 
with serologically positive results, such as toxoplasmosis, 
syphilis, hepatitis B or C, and other diseases that may result 
in some form of neurological disorder. Inclusion criteria 
were patients of both genders, from 35 to 60 years of age, 
who met the criteria according to the neuropsychological 
evaluation.
Parametric tests were used for normally distributed 
variables, Mann-Whitney test for nonparametric 
distributions, and the Spearman and Pearson’s r tests 
for analysis of correlation, where appropriate. One-way 
ANOVA - Dunnett tests were used to detect differences 
of telomere length, as a continuous variable. For the 
elaboration of graphs, we employed Graph Pad Software 
5.0 (La Jolla, CA, US). Statistical significance level was 
set at p≤0.05.
RESULTS
From the 73 patients included in this study and 
submitted to the neurological evaluation, 15 did not have 
a cognitive impairment whereas 49 were cognitively 
impaired and classified under one of the three categories 
of asymptomatic neurocognitive disorder (ANI), mild 
to moderate neurocognitive disorder (MND), and HIV-
associated dementia (HAD). 91 HIV-uninfected healthy 
individuals made up the control group for this study. 
The demographic and clinical characteristics of the 
patients are shown on Table 1. Only three patients had a 
detectable viral load in their cerebrospinal fluid. Of the 73 
HIV-1-infected patients, 20 (31.25%) were female and 44 
(68.75%) were male. The LTL was performed by qPCR for 
Table 1 - Demographical, laboratorial and clinical characteristics of the participants 
Variable Control 
n. (%)
Normal 
n. (%)
ANI 
n. (%)
MND 
n. (%)
HAD 
n. (%) p value
Total 91 15 26 13 10
Age* (years, SD) 46.79 (7.36) 46.73 (6.37) 49.31 (5.64) 52.0 (6.94) 49.7 (6.75) <0.0001
Gender 
     Male 
     Female
 
55/91 
36/91
 
11/15 
04/15
 
18/26 
08/26
 
10/13 
03/13
 
05/10 
0510
Education* (years) 15.58 (2.58) 15.67 (5.12) 11.50 (3.03) 11.46 (3.07) 8.00 (3.85) <0.0001
Infection * time HIV N.A. 11.80 (7.72) 9.80 (7.12) 10.31 (4.59) 15.10 (3.24) 0.0813
Current Smoker (%) 0 26.6 3.84 15.38 0
Physical* activity 3100 (2100) 2020 (2133) 2400 (3000) 2150 (2312) 1500 (1300) 0.0850
CPE rank* N.A. 5.13 (3.22) 7.00 (2.54) 5.23 (2.04) 7.40 (1.35) 0.0308
HIV RNA plasma N.A. 23 175 0 17
T CD4+ cells N.A. 753 (259) 650 (261) 677 (269) 463 (169) 0.0156
Telomere Length (T/S) 0.688 (0.229) 0.574 (0.210) 0.483 (0.168) 0.477 (0.219) 0.473 (0.058) <0.0001
Note: Groups classified as HIV negative controls; HIV-infected patients without neurocognitive impairments; ANI: Asymptomatic 
neurocognitive impairment; MND: Associated mild neurocognitive disorder; HAD: HIV-associated dementia. * represents the values 
of mean and standard deviation. Physical activity score is divided into: inactive: 0 to 500MET-min/week; modestly active: 600MET 
to 2999 MET-min / week; active: at least 3000MET-min/week. CPE rank: effectiveness score of antiretroviral drugs penetration in 
the central nervous system. HIV RNA Blood and CSF means detectable viral load (%). N.A: not applicable
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the HIV-infected positive patients and for the 91 healthy 
controls. 
Loss of TL with aging was observed for the control 
group (p = 0.0001). HIV-1-infected patients, including those 
both with and without neurocognitive disorder presented 
shorter age-matched telomere length in comparison to 
healthy individuals (p=0.0073). A statistically significant 
difference was found among HIV-infected patients: those 
without neurocognitive disorder had longer telomere 
lengths than those with cognitive impairment taking as 
a whole (p=0.01) (Figure 1). However, no significant 
difference in telomere length was found between HIV-
positive individuals without neurocognitive disorders and 
other groups when the comparison was made with each 
individual group (ANI, MND, HAD, respectively) (p=0.14; 
p=0.67; p=0.42), suggesting that this characteristic alone is 
not sufficient to differentiate the levels of neurocognitive 
disorders in HIV-positive patients.
Smoking was not associated with telomere length among 
HIV-positive individuals (p = 0.97), and so was physical 
activity (p=0.11) (Table 1). Other variables such as plasma 
viral load, time of infection, and CD+ T lymphocyte count 
were also not associated with TL (p=0.66; p=0.09; p = 0.84, 
respectively). Additionally, no difference on LTL was found 
between males and females (p = 0.80).
DISCUSSION
Some studies suggest that short telomeres cause an 
increase in neurocognitive impairment, which may lead to a 
risk of dementia in non-HIV infected populations27 and may 
be a marker for atypical cognitive decline related to age28,29, 
while another study pointed out that telomere length does 
not seem to provide a tool to predict cognitive decline30. 
Currently, there is an increasing incidence of all degrees 
of neurocognitive impairment in HIV-1-infected patients. 
Telomere length has been proposed as a possible marker 
for such neurocognitive alterations. In our study, we did not 
find an association between leukocytes, telomere lengths 
and age of patients who were not cognitively impaired. A 
limitation of our study is the small number of patients with 
HAD, probably due to the decrease in the incidence of the 
disorder after the beginning of HAART use in large scale. 
Previous studies have linked the shortening of telomeres 
with increasing neurocognitive changes, suggesting that 
it might be a marker27,28,31 and possibly involved in the 
accelerated cognitive aging of HIV-1-infected individuals.
Consistent with our findings, a previous study that 
searched for an association of telomere length with 
neurocognitive impairments in HIV-positive women did 
not find any was negative32. In contrast, another study 
suggested that telomere length might be a risk factor for 
the increasing susceptibility to neurocognitive decline in 
HIV-1- infected individuals31.
Furthermore, we examined whether some individual 
practices, harmful or beneficial, could influence telomere 
length. We could not find an association between tobacco 
smoking and LTL. Similarly, physical activity was also not 
associated with telomere length, contrary to the findings of 
another study29. Some studies suggested that telomere length 
is longer in women33,34, but this remains a controversial issue. 
We could not find a statistically significant difference in 
telomere length between genders in the current study.
As expected, older age was associated with telomere 
length shortening. Other studies have reached similar 
results, independently of the HIV status3,35. There was a 
significant difference in the telomere length in leukocytes 
between HIV-infected individuals compared to our HIV-
negative healthy controls36,37. Similarly, a study showed 
that CD8+ T cells from HIV-infected individuals had 
shorter telomeres than the same cells from HIV-negative 
subjects, reflecting the impact of viral infection on the 
senescence of that cellular compartment. The same study 
did not find the same abnormalities on CD4+ T cells38. We 
have not performed a study using T cell subpopulations 
to test this hypothesis. We suggest that the investigation 
of lymphocytes should be performed with purified cells 
instead of total leukocytes.
In conclusion, telomere shortening was not associated 
with neurocognitive impairment in our HIV-infected 
patients and did not act as a cellular aging biomarker in this 
population. Further studies are needed to better understand 
the mechanisms of HIV infection and senescence in patients 
with different degrees of neurocognitive disorders. 
Figure 1 - Telomere length from HIV patients and healthy 
controls according to their respective performances on 
neuropsychological tests
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